Fontenay aux Roses, France

Nathalie Schussler

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nathalie Schussler: Innovator in Alzheimer's Disease Treatment

Introduction

Nathalie Schussler is a prominent inventor based in Fontenay aux Roses, France. She has made significant contributions to the field of neurodegenerative diseases, particularly in the treatment of Alzheimer's disease. Her innovative work has led to the development of a unique patent that addresses critical challenges in this area.

Latest Patents

Nathalie Schussler holds a patent for an H3 receptor antagonist aimed at treating Alzheimer's disease. This patent, which is titled "Methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases," represents a significant advancement in disease-modifying therapies.

Career Highlights

Nathalie is currently employed at Sanofi, a leading global healthcare company. Her work at Sanofi has allowed her to focus on innovative solutions for complex medical conditions. With her expertise, she has contributed to the advancement of treatments that can potentially improve the quality of life for patients suffering from Alzheimer's disease.

Collaborations

Throughout her career, Nathalie has collaborated with notable colleagues, including Pascal Barneoud and Veronique Blanchard-Bregeon. These collaborations have fostered a productive environment for research and development, enhancing the impact of their collective work in the field.

Conclusion

Nathalie Schussler's contributions to the treatment of Alzheimer's disease through her innovative patent exemplify her dedication to advancing medical science. Her work at Sanofi and collaborations with esteemed colleagues further highlight her role as a key player in the fight against neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…